Introduction
============

With the development of high throughput technology and gene data analysis over the past decade, rapid progress has been made in discovering genetic associations of diseases ([@b1-etm-0-0-7410],[@b2-etm-0-0-7410]). Generally, genes do not work individually, but co-operate with each other and actively participate in biological processes systemically. To the best of our knowledge, pathway analysis is the first choice for shedding light on underlying biology of genes in many diseases ([@b3-etm-0-0-7410]).

In the present study, using pathway annotations and gene expression data, we proposed to predict optimal pathways for PE patients by integrating the guilt by association (GBA) algorithm and network approach, termed with network-based GBA inference method. Co-expression network (CEN) of differentially expressed genes (DEGs) was constructed by the Spearman\'s correlation coefficient (SCC) method. Pathway data for PE were collected dependent on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and DEGs. Ultimately, the network-based GBA inference method was implemented to predict optimal pathways, of which the area under the receiver operating characteristics curve (AUROC) was obtained for each pathway. The results might provide new insights on uncovering molecular mechanism underlying PE.

Materials and methods
=====================

### Preparing gene expression data and DEGs

To control the quality gene array E-GEOD-25906 from ArrayExpress database was used. This dataset includes larger number of subjects relatively less affected by other factors. The diagnostic standard with preeclampsia (PE) clinical inclusion criteria of the subjects: women were diagnosed with PE if their systolic blood pressure was at least 140 mmHg, their diastolic blood pressure was at least 90 mmHg and they had proteinuria with an estimated 300 mg of protein or greater excreted in 24 h measured directly or indirectly by protein creatinine ratio. Standard pretreatments were conducted, containing background correction ([@b4-etm-0-0-7410]), normalization ([@b5-etm-0-0-7410]), probe match ([@b6-etm-0-0-7410]) and summarization of expressed values ([@b4-etm-0-0-7410]). After converting the preprocessed data on probe level into gene symbol measure and removing the duplicated ones, we obtained a total of 19,027 genes in gene expression data.

The lmFit function implemented in Limma was utilized to perform empirical Bayes statistics and false discovery rate (FDR) calibration of the P-values on the data ([@b7-etm-0-0-7410]--[@b9-etm-0-0-7410]). Only genes which met to the thresholds of P\<0.01 and \|log~2~FoldChange\| \>2 were defined as DEGs across PE patients and normal controls.

### Constructing CEN

In order to illustrate the relationships among DEGs of PE samples, the SCC method was utilized ([@b10-etm-0-0-7410]). Besides, for an interaction between gene *x* and *y*, the SCC was computed as follows:
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Note that the absolute SCC value across PE samples and normal controls was denoted as its weight value. The larger of the weight value, the closer of the interaction between two genes was. Next, DEGs and weight values were input into the Cytoscape software to visualize the CEN. Consequently, a CEN with weights was obtained for subsequent analysis.

### Recruiting pathway annotation data

Metabolism pathways were recruited from the KEGG pathway database ([@b11-etm-0-0-7410]). There are 287 pathways covering 6,894 genes in the KEGG pathway database. Subsequently, with an attempt to make these pathways more closely correlated with PE patients, all DEGs were mapped to 287 pathways, and only pathways that had intersections with DEGs were left to the remaining analyses, named as pathway annotation data.

### Network-based GBA inference method

All DEGs were mapped to 287 pathways, and the pathways that had intersections with DEGs were left for pathway annotation data. In this work, the network-based GBA inference method was employed to predict pathway functions in the development of PE patients, which combined CEN with the GBA algorithm ([@b12-etm-0-0-7410]). Taking pathway as our source of functional annotations, a multi-functionality score (MFS) was assigned to each gene *i* in the CEN ([@b13-etm-0-0-7410]), Where *Num~ink~* was the number of genes within pathway group *k*, whose weighting had the effect of giving contribution to a pathway group.
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Where *Num~ink~* was the number of genes within pathway group *k*, weighting exerted the action of giving contribution to a pathway group; and *Num~outk~* was the number of genes outside pathway group in the CEN. Where *Num~ink~* was the number of genes within pathway group *k*, whose weighting had the effect of giving contribution to a pathway group. In subsequent analysis, we computed the AUROC values for assessing the classification performances between PE samples and normal controls ([@b14-etm-0-0-7410]). Consequently, the AUROC for each pathway was obtained, and we selected these pathways of AUROC \>0.5 as optimal pathways of PE patients.

Results
=======

### DEGs and pathway data

As described above, a total of 19,027 genes were identified in E-GEOD-25906 after standard pretreatments. Using the Limma package, we determined 351 DEGs between PE patients and normal controls which satisfied the thresholds of P\<0.01 and \|log~2~FoldChange\| \>2. Significantly, the top five genes in descending order of their P-values were SIAE (P=4.59E-10), TRIM24 (P=7.48E-10), PPP1R12C (P=2.90E-09), TUBA1B (P=3.96E-09), and ENG (P=4.23E-09).

The total 287 pathways (involving 6,894 genes) belonging to metabolism category were collected from the KEGG pathway database. In addition, 351 DEGs of PE patients were mapped to 287 pathways to make these pathways more correlated to PE patients, and we only took the intersections. As a result, 81 pathways including 300 DEGs were reserved as pathway annotation data for subsequent study ([Table I](#tI-etm-0-0-7410){ref-type="table"}), such as Protein processing in endoplasmic reticulum (ID: hsa04141), Ribosome (ID: hsa03010), and Purine metabolism (ID: hsa00230).

### CEN

To describe relationships among DEGs clearly, the SCC method was implemented to weight the strength between a pair of genes, and those weighted interactions were input into Cytoscape and visualized as the CEN for PE patients. A total of 351 nodes and 61,425 edges were deposited on the CEN, which suggested that all DEGs were mapped to the network. The edge between KPNA2 and MAT2B (weight=0.9986), FSTL3 and SKIDA1 (weight=0.9984), SSNA1 and PFDN6 (weight=0.9984) had higher weights than the other interactions. Noteworthy, a good liner correlation was uncovered among weights. Additionally, topological centrality analysis on nodes in the CEN of PE was conducted by summing up the nodes it connected directly. We found that the degree distribution for six nodes was not \<200, including RDH13 (degree=202), SELENOS (degree=201), PAPPA2 (degree=201), RASSF7 (degree=201), DNAJC3 (degree=200) and PPP1R12C (degree=200).

### Optimal pathways

Utilizing pathway annotation data, we identified optimal pathways through gene function inference dependent on the network-based GBA method. During this process, an MFS was produced for each pathway. Importantly, we carried out 3-fold cross-validation on MFS to calculate AUROC for pathways. The AUROC distribution among GO terms is illustrated in [Fig. 1](#f1-etm-0-0-7410){ref-type="fig"}. We found that the AUROC for large amount of pathways distributed to the section of 0.4--0.6 and 0.75--0.9. Accordingly, 53 pathways had AUROC \>0.5. Furthermore, 9 of 53 pathways with AUROC \>0.9 were denoted as optimal pathways, specifically microRNAs in cancer (AUROC=0.9966), gap junction (AUROC=0.9922), pathogenic *Escherichia coli* infection (AUROC=0.9888), phagosome (AUROC=0.9881), ovarian steroidogenesis (AUROC=0.9821), viral carcinogenesis (AUROC=0.9642), MAPK signaling pathway (AUROC=0.9473), tuberculosis (AUROC=0.9428), and tight junction (AUROC=0.9136).

Discussion
==========

Our results showed that 53 pathways were provided with a good classification performance with AUROC \>0.5, 9 of AUROC with \>0.9 were defined as optimal pathways, which included microRNAs in cancer, gap junction, pathogenic *Escherichia coli* infection, phagosome, ovarian steroidogenesis, viral carcinogenesis, MAPK signaling pathway, tuberculosis, and tight junction.

We confirmed that the optimal pathway microRNAs in cancer play a significant role in tumor issues, but the functions for this pathway in PE patients has been reported ([@b15-etm-0-0-7410]). Furthermore, Bird *et al* focused on pregnancy endothelial adaptive failure in PE ([@b16-etm-0-0-7410]). Gap junction implicated modulatory intercellular communication during gestation in accordance with regulation of vascular tone ([@b17-etm-0-0-7410]). Hence gap junction was closely related to PE patients. Our results showed that 53 pathways had a good classification performance with AUROC \>0.5, 9 of AUROC were \>0.9 and defined as optimal pathways, which included microRNAs in cancer, gap junction, pathogenic *Escherichia coli* infection, phagosome, ovarian steroidogenesis, viral carcinogenesis, MAPK signaling pathway, tuberculosis, and tight junction.

BMP6 and HSD17B2 were enriched in ovarian steroidogenesis pathway as one of optimal pathways. From previous studies, hydroxysteroid (17-β) dehydrogenase 1, encoded by HSD17B1, was found to be significantly decreased in PE patients and was identified to be an independent risk factor for PE ([@b18-etm-0-0-7410],[@b19-etm-0-0-7410]), thus, it will be proposed as a potential prognostic factor for PE. Additionally, MAPK signaling pathway has been paid increasing attention by demonstrating it to participate in PE progression as a crucial pathogenesis of PE ([@b20-etm-0-0-7410]--[@b22-etm-0-0-7410]).

In conclusion, 9 optimal pathways were disclosed for PE patients by network-based GBA algorithm, which might shed new lights on unraveling the molecular and pathological mechanism of PE. However, validations of these pathways are still not covered, and future studies should be focused on this aspect.

Not applicable.

Funding
=======

No funding was received.

Availability of data and materials
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors\' contributions
=======================

YR, YL and YPL conceived the study, analyzed the data and drafted the manuscript. JZ, XW and WZ performed the experiments, analyzed the data and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

Not applicable.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![The AUROC distribution among GO terms. AUROC for large amount of pathways distributed to the section of 0.4--0.6 and 0.75--0.9.](etm-17-05-4139-g02){#f1-etm-0-0-7410}

###### 

KEGG pathway annotation data for PE.

  Pathway ID   Pathway name                                               DEGs
  ------------ ---------------------------------------------------------- ----------------------------------------------------------
  hsa00010     Glycolysis/Gluconeogenesis                                 PGAM1; HK2
  hsa00230     Purine metabolism                                          POLR2H; RRM1; DCK; PDE8B; HPRT1
  hsa00240     Pyrimidine metabolism                                      POLR2H; RRM1; DCK
  hsa00270     Cysteine and methionine metabolism                         MAT2B; GOT1
  hsa00350     Tyrosine metabolism                                        MIF; GOT1
  hsa00360     Phenylalanine metabolism                                   MIF; GOT1
  hsa00480     Glutathione metabolism                                     GCLM; TXNDC12; RRM1
  hsa00520     Amino sugar and nucleotide sugar metabolism                HEXB; GNPDA1; HK2
  hsa00531     Glycosaminoglycan degradation                              HEXB; GNS
  hsa00564     Glycerophospholipid metabolism                             PLA2G16; MBOAT1
  hsa00650     Butanoate metabolism                                       L2HGDH; HMGCS1
  hsa00900     Terpenoid backbone biosynthesis                            HMGCS1; PDSS2
  hsa01200     Carbon metabolism                                          PGAM1; GPT2; GOT1; HK2
  hsa01210     2-Oxocarboxylic acid metabolism                            GPT2; GOT1
  hsa01230     Biosynthesis of amino acids                                PGAM1; MAT2B; GPT2; GOT1
  hsa02010     ABC transporters                                           ABCA7; ABCB6
  hsa03008     Ribosome biogenesis in eukaryotes                          WDR75; MPHOSPH10; NVL
  hsa03010     Ribosome                                                   RPL7A; MRPS5; RPL18A; RPS2; MRPL14
  hsa03013     RNA transport                                              TPR; ALYREF; UPF3B; SUMO3
  hsa03015     mRNA surveillance pathway                                  ALYREF; UPF3B
  hsa03018     RNA degradation                                            BTG1; HSPD1; LSM7
  hsa03040     Spliceosome                                                SYF2; ALYREF; LSM7
  hsa04010     MAPK signaling pathway                                     MAP4K3; RRAS2; GNG12
  hsa04014     Ras signaling pathway                                      RGL2; GNG2; RRAS2; GNG12; PLA2G16
  hsa04020     Calcium signaling pathway                                  SLC25A5; PHKA2
  hsa04062     Chemokine signaling pathway                                GNG2; GNG12
  hsa04068     FoxO signaling pathway                                     CSNK1E; GABARAPL2; PRKAB2
  hsa04141     Protein processing in endoplasmic reticulum                DNAJC3; OS9; HSP90B1; SSR1; DNAJB11; UGGT2; DNAJB2; SSR4
  hsa04142     Lysosome                                                   GNPTG; CTSC; HEXB; CTSA; GNS
  hsa04145     Phagosome                                                  TUBA1B; ACTG1; TUBA1A
  hsa04151     PI3K-Akt signaling pathway                                 JAK1; COL27A1; HSP90B1; GNG2; GNG12
  hsa04152     AMPK signaling pathway                                     LEP; STRADB; ACACB; PRKAB2
  hsa04310     Wnt signaling pathway                                      CSNK1E; FZD7
  hsa04360     Axon guidance                                              SEMA4C; SEMA3B
  hsa04390     Hippo signaling pathway                                    SNAI2; ACTG1; CSNK1E; BMP6; FZD7
  hsa04510     Focal adhesion                                             PPP1R12C; COL27A1; ACTG1
  hsa04520     Adherens junction                                          SNAI2; ACTG1; PTPRB
  hsa04530     Tight junction                                             ACTG1; YBX3; RRAS2
  hsa04540     Gap junction                                               TUBA1B; TUBA1A
  hsa04550     Signaling pathways regulating pluripotency of stem cells   JAK1; FZD7
  hsa04610     Complement and coagulation cascades                        F13A1; CFB; TFPI
  hsa04611     Platelet activation                                        COL27A1; ACTG1
  hsa04614     Renin-angiotensin system                                   MME; CTSA; ACE2
  hsa04630     Jak-STAT signaling pathway                                 JAK1; LEP
  hsa04640     Hematopoietic cell lineage                                 MME; CD24
  hsa04710     Circadian rhythm                                           CSNK1E; CLOCK; PRKAB2
  hsa04713     Circadian entrainment                                      GNG2; GNG12
  hsa04723     Retrograde endocannabinoid signaling                       GNG2; GNG12
  hsa04724     Glutamatergic synapse                                      GNG2; GNG12
  hsa04725     Cholinergic synapse                                        GNG2; GNG12
  hsa04726     Serotonergic synapse                                       GNG2; GNG12
  hsa04727     GABAergic synapse                                          GABARAPL2; GNG2; GNG12
  hsa04728     Dopaminergic synapse                                       GNG2; CLOCK; GNG12
  hsa04810     Regulation of actin cytoskeleton                           PPP1R12C; ACTG1; RRAS2; GNG12
  hsa04910     Insulin signaling pathway                                  PHKA2; ACACB; HK2; PRKAB2
  hsa04913     Ovarian steroidogenesis                                    BMP6; HSD17B2
  hsa04919     Thyroid hormone signaling pathway                          ACTG1; NCOA2; MED27; RCAN1
  hsa04920     Adipocytokine signaling pathway                            LEP; ACACB; PRKAB2
  hsa04921     Oxytocin signaling pathway                                 PPP1R12C; ACTG1; RCAN1; PRKAB2
  hsa04922     Glucagon signaling pathway                                 PGAM1; PHKA2; ACACB; PRKAB2
  hsa04932     Non-alcoholic fatty liver disease (NAFLD)                  CEBPA; NDUFA12; LEP; PRKAB2
  hsa04974     Protein digestion and absorption                           COL27A1; MME; ACE2; KCNN4; COL15A1
  hsa05010     Alzheimer\'s disease                                       NDUFA12; MME
  hsa05012     Parkinson\'s disease                                       NDUFA12; SLC25A5; UBB
  hsa05016     Huntington\'s disease                                      NDUFA12; SLC25A5; POLR2H
  hsa05032     Morphine addiction                                         GNG2; GNG12; PDE8B
  hsa05034     Alcoholism                                                 H2AFY; HIST2H2AC; GNG2; GNG12
  hsa05130     Pathogenic *Escherichia coli* infection                    TUBA1B; ACTG1; TUBA1A
  hsa05152     Tuberculosis                                               JAK1; HSPD1; BCL10
  hsa05161     Hepatitis B                                                JAK1; LAMTOR5
  hsa05164     Influenza A                                                DNAJC3; JAK1; ACTG1; KPNA2
  hsa05166     HTLV--I infection                                          JAK1; SLC25A5; RANBP1; RRAS2; FZD7
  hsa05168     Herpes simplex infection                                   JAK1; ALYREF; CLOCK
  hsa05169     Epstein-Barr virus infection                               JAK1; VIM; POLR2H; AKAP8L
  hsa05200     Pathways in cancer                                         CEBPA; TPR; JAK1; HSP90B1; GNG2; GNG12; FZD7
  hsa05203     Viral carcinogenesis                                       JAK1; RANBP1
  hsa05205     Proteoglycans in cancer                                    PPP1R12C; ACTG1; RRAS2; FZD7
  hsa05206     MicroRNAs in cancer                                        FSCN1; VIM
  hsa05230     Central carbon metabolism in cancer                        PGAM1; HK2
  hsa05322     Systemic lupus erythematosus                               H2AFY; HIST2H2AC
  hsa05410     Hypertrophic cardiomyopathy (HCM)                          ACTG1; PRKAB2
